Browsing by Subject "PKA"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells
    (Wiley, 2023-02) Alaskar, Aljoharah; Abdulraqeb Ali, Amaal; Hassan, Sazzad; Shinwari, Zakia; Alaiya, Ayodele; von Holzen, Urs; Miller, Lance; Kulik, George; Surgery, School of Medicine
    Background There is accumulating evidence that propranolol, an antagonist of beta-1 and beta-2 adrenoreceptors, extends survival of patients with prostate cancer; yet it is not known whether propranolol inhibits beta-adrenergic signaling in prostate cancer cells, or systemic effects of propranolol play the leading role in slowing down cancer progression. Recently initiated clinical studies offer a possibility to test whether administration of propranolol inhibits signaling pathways in prostate tumors, however, there is limited information on the dynamics of signaling pathways activated downstream of beta-2 adrenoreceptors in prostate cancer cells and on the inactivation of these pathways upon propranolol administration. Methods Western blot analysis was used to test the effects of epinephrine and propranolol on activation of protein kinase (PKA) signaling in mouse prostates and PKA, extracellular signal-regulated kinase (ERK), and protein kinase B/AKT (AKT) signaling in prostate cancer cell lines. Results In prostate cancer cell lines epinephrine induced robust phosphorylation of PKA substrates pS133CREB and pS157VASP that was evident 2 min after treatments and lasted for 3−6 h. Epinephrine induced phosphorylation of AKT in PTEN-positive 22Rv1 cells, whereas changes of constitutive AKT phosphorylation were minimal in PTEN-negative PC3, C42, and LNCaP cells. A modest short-term increase of pERK in response to epinephrine was observed in all tested cell lines. Incubation of prostate cancer cells with 10-fold molar excess of propranolol for 30 min inhibited all downstream pathways activated by epinephrine. Subjecting mice to immobilization stress induced phosphorylation of S133CREB, whereas injection of propranolol at 1.5 mg/kg prevented the stress-induced phosphorylation. Conclusions The analysis of pS133CREB and pS157VASP allows measuring activation of PKA signaling downstream of beta-2 adrenoreceptors. Presented results on the ratio of propranolol/epinephrine and the time needed to inhibit signaling downstream of beta-2 adrenoreceptors will help to design clinical studies that examine the effects of propranolol on prostate tumors.
  • Thumbnail Image
    Item
    Long-term exposure to PGE2 causes homologous desensitization of receptor-mediated activation of protein kinase A
    (Springer (Biomed Central Ltd.), 2016-07-11) Malty, Ramy Habashy; Hudmon, Andy; Fehrenbacher, Jill C.; Vasko, Michael R.; Department of Pharmacology and Toxicology, IU School of Medicine
    BACKGROUND: Acute exposure to prostaglandin E2 (PGE2) activates EP receptors in sensory neurons which triggers the cAMP-dependent protein kinase A (PKA) signaling cascade resulting in enhanced excitability of the neurons. With long-term exposure to PGE2, however, the activation of PKA does not appear to mediate persistent PGE2-induced sensitization. Consequently, we examined whether homologous desensitization of PGE2-mediated PKA activation occurs after long-term exposure of isolated sensory neurons to the eicosanoid. METHODS: Sensory neuronal cultures were harvested from the dorsal root ganglia of adult male Sprague-Dawley rats. The cultures were pretreated with vehicle or PGE2 and used to examine signaling mechanisms mediating acute versus persistent sensitization by exposure to the eicosanoid using enhanced capsaicin-evoked release of immunoreactive calcitonin gene-related peptide (iCGRP) as an endpoint. Neuronal cultures chronically exposed to vehicle or PGE2 also were used to study the ability of the eicosanoid and other agonists to activate PKA and whether long-term exposure to the prostanoid alters expression of EP receptor subtypes. RESULTS: Acute exposure to 1 μM PGE2 augments the capsaicin-evoked release of iCGRP, and this effect is blocked by the PKA inhibitor H-89. After 5 days of exposure to 1 μM PGE2, administration of the eicosanoid still augments evoked release of iCGRP, but the effect is not attenuated by inhibition of PKA or by inhibition of PI3 kinases. The sensitizing actions of PGE2 after acute and long-term exposure were attenuated by EP2, EP3, and EP4 receptor antagonists, but not by an EP1 antagonist. Exposing neuronal cultures to 1 μM PGE2 for 12 h to 5 days blocks the ability of PGE2 to activate PKA. The offset of the desensitization occurs within 24 h of removal of PGE2 from the cultures. Long-term exposure to PGE2 also results in desensitization of the ability of a selective EP4 receptor agonist, L902688 to activate PKA, but does not alter the ability of cholera toxin, forskolin, or a stable analog of prostacyclin to activate PKA. CONCLUSIONS: Long-term exposure to PGE2 results in homologous desensitization of EP4 receptor activation of PKA, but not to neuronal sensitization suggesting that activation of PKA does not mediate PGE2-induced sensitization after chronic exposure to the eicosanoid.
  • Thumbnail Image
    Item
    Phosphorylation State Modulates the Interaction between Spinophilin and Neurofilament Medium
    (2015-04-07) Hiday, Andrew C.; Baucum, Anthony J.
    A histological marker of Parkinson’s disease (PD) is the loss of synapses located on striatal medium spiny neurons (MSNs) as a result of dopaminergic nigral cell depletion. The dendritic spines that give MSNs their name have a well-characterized structure and are the main regions of post-synaptic input. It has been shown that spines have altered functionality and morphology in many neurodegenerative diseases. Spine morphology, and potentially function, is dictated by an array of structural proteins and their associations with other proteins in a region dubbed the post-synaptic density (PSD). Spinophilin and neurofilament medium (NF-M) are two proteins that are enriched in the PSD and have potential implications in PD. Interestingly, preliminary data show that there is a decrease in the NF-M-spinophilin interaction in animal models of PD. Here it is shown that these two proteins interact in brain tissue and when overexpressed in a mammalian cell system. Moreover, we have begun to determine mechanisms that regulate this interaction. It is known that there is a misregulation of protein phosphatases and kinases in many neurodegenerative diseases. Moreover, the phosphorylation state of a protein can regulate its association with other proteins. Therefore, we hypothesize that the phosphorylation state of either protein affects the interaction between spinophilin and NF-M. Furthermore, we have conducted experiments utilizing protein phosphatases and kinases that are known to modulate the phosphorylation state of NF-M and/or spinophilin. Data show that both kinase and phosphatase activity and/or expression modulates the NF-M-spinophilin interaction in heterologous cell lines. Through the use of MS/MS analysis, we have begun to map specific phosphorylation sites that may play a role in regulating this interaction. Currently, we are elucidating the specific effects of these post-translational modifications on regulating the spinophilin-NF-M interaction. These data will enhance our knowledge of spinophilin’s interactions and how these interactions are altered in neurological disorders such as PD.